Related Experiment Video
Updated: Jul 10, 2026
10:04
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
New therapies in multiple myeloma.
F Merchionne1, F Perosa, F Dammacco
1Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Policlinico, Piazza Giulio Cesare 11, I-70124 Bari, Italy. framerk@hotmail.com
Clinical and Experimental Medicine
|November 1, 2007
Summary
Novel agents like thalidomide, bortezomib, and lenalidomide offer new hope for multiple myeloma (MM) patients, improving outcomes beyond traditional chemotherapy and stem-cell support.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Melphalan-prednisone was standard for multiple myeloma (MM).
- High-dose chemotherapy with stem-cell support improves survival but most patients relapse.
- Salvage treatments are often ineffective.
Purpose of the Study:
- To review novel agents for multiple myeloma (MM).
- To discuss thalidomide, bortezomib, and lenalidomide in MM treatment.
- To highlight their efficacy in overcoming chemoresistance and improving patient survival.
Main Methods:
- Review of significant clinical trials involving thalidomide, bortezomib, and lenalidomide.
- Analysis of treatment outcomes in relapsed, refractory, and newly diagnosed MM patients.
- Evaluation of novel drug combinations and their impact on survival.
Main Results:
- Thalidomide shows efficacy in response rate and event-free survival, especially in combination regimens.
- Bortezomib demonstrates remarkable activity in relapsed/refractory and newly diagnosed MM.
- Lenalidomide with dexamethasone achieves high response rates in relapsed/refractory MM and shows promise in first-line therapy.
Conclusions:
- Novel agents like thalidomide, bortezomib, and lenalidomide are effective in multiple myeloma (MM).
- These drugs overcome resistance and target the tumor microenvironment.
- Ongoing studies aim to identify optimal combinations for improved MM survival.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...